HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Amaurosis fugax: prognosis and the role of acetylsalicylic acid.

Abstract
Amaurosis fugax has been grouped together with other forms of transient ischemic attacks (TIAs) in the neurologic literature in analyses of prognosis. Although episodes of transient visual loss (TVL) are presumed to be due to ischemia, the prognosis with respect to subsequent stroke and myocardial infarct (MI) appears to differ from cerebral TIAs. We reviewed the clinical course of 73 patients above the age of 45 years who presented to our clinics with a distinct history of TVL. With an average follow-up period of 38 months, the incidence rates of cerebrovascular accident, cerebral TIA and MI following presentation with TVL were 1%, 4% and 7% respectively. Although there was a trend toward fewer episodes of amaurosis with use of acetylsalicylic acid (ASA), the difference was not statistically significant. In addition, ASA did not appear to offer a benefit with respect to future ischemic events. Patients with monocular TVL appeared more likely to experience a TIA, whereas those with binocular TVL appeared more likely to experience an MI.
AuthorsM Gans, D Anderson
JournalCanadian journal of ophthalmology. Journal canadien d'ophtalmologie (Can J Ophthalmol) Vol. 29 Issue 3 Pg. 115-8 (Jun 1994) ISSN: 0008-4182 [Print] England
PMID7922849 (Publication Type: Journal Article)
Chemical References
  • Aspirin
Topics
  • Aged
  • Aged, 80 and over
  • Aspirin (therapeutic use)
  • Blindness (etiology, prevention & control)
  • Brain Ischemia (complications, etiology)
  • Cerebrovascular Disorders (complications)
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Myocardial Infarction (complications)
  • Prognosis
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: